EHA 2023 | The benefit of bispecific antibodies & CAR-T therapy in triple class-exposed multiple myeloma
Albert Oriol
• 9 Jun 2023
Albert Oriol, MD, PhD, Josep Carreras Leukaemia Research Institute, Barcelona, Spain, emphasizes the importance of using novel therapies like CAR-T and bispecific antibodies in patients with triple class-exposed multiple myeloma, explaining that treating patients with drugs they have previously been exposed to only provides a modest benefit. Dr Oriol also states the benefit of using CAR-T therapy before bispecifics if the therapy is available. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
